Compare FTLF & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | ALDX |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 124.9M |
| IPO Year | 2006 | 2014 |
| Metric | FTLF | ALDX |
|---|---|---|
| Price | $10.25 | $1.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $21.50 | $5.50 |
| AVG Volume (30 Days) | 33.1K | ★ 1.9M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $21,744,000.00 | N/A |
| Revenue This Year | $45.76 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $60.29 | ★ N/A |
| Revenue Growth | ★ 11.52 | N/A |
| 52 Week Low | $8.67 | $1.07 |
| 52 Week High | $20.98 | $6.18 |
| Indicator | FTLF | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 34.43 |
| Support Level | $10.25 | $1.49 |
| Resistance Level | $11.39 | $1.91 |
| Average True Range (ATR) | 0.42 | 0.15 |
| MACD | -0.14 | -0.07 |
| Stochastic Oscillator | 16.13 | 3.43 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Dr. Tobias, MusclePharm, Irwin Naturals, Applied Nutrition, Isatori, and Nature's Secret brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.